Navigation Links
Heska Announces Q310 Results
Date:11/15/2010

LOVELAND, Colo., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA, "Heska" or the "Company") today reported financial results for its third quarter ended September 30, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20000622/HESKALOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)

"These results exceed our revenue expectations and most recent revenue guidance.  We had a particularly strong quarter in our Other Vaccines, Pharmaceuticals and Products segment where the USDA validated an improved process for our line of cattle vaccines, allowing us to ship a significant quantity of product in a category which had previously been on hold due to regulatory discussions," said Robert Grieve, Heska's Chairman and CEO.  "As we have reported over the course of 2010, we faced a difficult year-over-year comparison in our Core Companion Animal Health segment as we are no longer selling the old line of handheld blood analysis instruments and affiliated consumables.  This product area accounted for over $2.7 million in revenue in the third quarter of 2009, with no such revenue in the third quarter of 2010."

Investor Conference CallManagement will conduct a conference call on Monday, November 15, 2010 at 9:00 a.m. MST (11:00 a.m. EST) to discuss the third quarter 2010 financial results.  To participate, dial (800) 762-8779 (domestic) or (480) 629-9771 (international); the conference call access number is 4371990.  The conference call will also be broadcast live over the Internet at http://www.heska.com.  To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software.  Telephone replays of the conference call will be available for playback until November 29, 2010.  The telephone replay may be accessed by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international).  The webcast replay may be accessed from Heska's home page at www.heska.com until November 29, 2010.

About HeskaHeska Corporation (Nasdaq: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products.  Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines.  The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.  For further information on Heska and its products, visit the company's website at www.heska.com.

Forward-Looking StatementsThis announcement contains forward-looking statements regarding Heska's future financial and operating results.  These statements are based on current expectations and are subject to a number of risks and uncertainties.  Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes.  For example, while Heska generated positive net income this quarter, there can be no assurance Heska will generate positive net income, or avoid a loss, in any future period.  In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to Heska's ability to maintain regulatory compliance for products it sells; risks related to competition and Heska's ability to compete economically in the marketplace; uncertainties related to the performance of third parties to whom Heska has granted substantial marketing rights including, but not limited to, Schering-Plough Animal Health Corporation; risks related to Heska's ability to maintain its listing on the NASDAQ Capital Market; uncertainties related to Heska's ability to market and sell its products successfully and economically; uncertainties related to Heska's ability to generate cash flow in any future periods; risks related to Heska's reliance on third-party suppliers, which is significant, including Heska's ability to meet its commitments to such suppliers; risks related to Heska's reliance on its revolving line of credit and Heska's ability to meet financial and other covenants to maintain access to such line of credit; uncertainties related to the impact of transfer restrictions on Heska's stock, which were approved by Heska stockholders at Heska's Annual Meeting of Stockholders on May 4, 2010; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010.Financial Table Follows:Consolidated Statements of Operations

In Thousands, Except per Share Amounts

(unaudited)Three Months EndedSeptember 30,Nine Months Ended
September 30,2009201020092010Revenue, net:Core companion animal health

$

16,89214,144$

51,908$

43,667Other vaccines, pharmaceuticals and products2,6583,4916,4126,769Total revenue, net 19,55017,63558,32050,436Cost of revenue12,13011,04236,49631,791Gross profit7,4206,59321,82418,645Operating expenses:Selling and marketing3,6953,91211,07511,604Research and development4574551,3081,300General and administrative2,1091,8616,2556,071Total operating expenses6,2616,22818,63818,975Operating income (loss) 1,1593653,186(330)Interest and other (income) expense, net(13)(118)193177Income (loss) before income taxes1,1724832,993(507)Income tax expense (benefit)4292421,211(253)Net income (loss)

$

743$

241$

1,782$

(254)Basic net income (loss) per share

$

0.01$

0.00$

0.03$

(0.00)Diluted net income (loss) per share

$

0.01$

0.00$

0.03$

(0.00)Shares used for basic net income (loss) per share52,12352,23752,04952,188Shares used for diluted net income (loss) per share52,19252,37652,06052,188Balance Sheet Data

In Thousands (unaudited)December 31,2009September 30,2010Cash and cash equivalents$

5,400$

5,745Total current assets28,49328,358Total assets64,13464,433Line of credit4,2014,989Current portion of long-term debt381-Total current liabilities14,10714,366Stockholders' equity45,05545,277
'/>"/>

SOURCE Heska Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer
2. Heska to Present at SunTrust Robinson Humphrey 1st Annual Veterinary Conference
3. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2009 Earnings Conference Call Webcast
4. Heska Announces Extension of Credit Agreement With Wells Fargo
5. Heska Announces Supply Agreement With Roche Diagnostics
6. Heska Announces Launch of New Website
7. Heska Announces Q309 Results
8. Parascript Announces AccuDetect 4.0, Computer-Aided Detection (CAD) for Mammography
9. Adeona Announces Third Quarter 2010 Financial Results and Achievements
10. BioWa Announces License of POTELLIGENT® Technology to Agensys
11. Dehaier Medical Announces Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... -- MACRA replaces the outdated sustainable growth rate ... Black Book Research crowdsource-surveyed 8,845 physician practices from February ... for MIPS Compliance Technology is Booming ... or more clinicians seek to buy Merit-Based Incentive Payment ... of the changes, the hunt is on for the ...
(Date:5/6/2017)...  May is Stroke Awareness Month and Omron Healthcare ... methods to prevent a stroke: monitor and manage your ... and Prevention, undetected and uncontrolled hypertension is a leading ... leader in personal heart health technology, recently evolved its ... and stroke and is advancing a national public education ...
(Date:5/4/2017)... 4, 2017  A recent study published in ... Ultraviolet-C light as a means of disinfection anesthesia ... reduce bioburden on anesthesia workstations. In the study, ... complex medical equipment surfaces contaminated with three (3) ... "This study further validates the body of literature ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... ... Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As ... latest advancements in his field by attending numerous CE courses each year. His ...
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan ... dentistry options for its patients on Long Island, New York. , Holistic ... being, and is one of the biggest trends in dentistry today. , ...
(Date:5/24/2017)... ... 2017 , ... Dymedix® Diagnostics, Inc., the leading ... had completed the first phase of building a global distribution network. To date, ... (ROW) authorized dealers specializing in polysomnography accessories. The company plans to expand ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, ... steady since 2009, according to a Workers Compensation Research Institute (WCRI) study, a ... the North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new ... building collagen and elastin in their face, neck, and body through a virtually ...
Breaking Medicine News(10 mins):